Entering text into the input field will update the search result below

AstraZeneca's Faslodex OK'd in Europe for first line advanced breast cancer

Jul. 26, 2017 3:17 PM ETAstraZeneca PLC (AZN) StockAZNBy: Douglas W. House, SA News Editor
  • The European Commission (EC) approves AstraZeneca's (AZN +0.5%) FASLODEX (fulvestrant) for the treatment of estrogen receptor-positive locally advanced or metastatic breast cancer in postmenopausal women who have not received prior endocrine therapy.
  • The EC based its decision on the successful outcome of the Phase 3 FALCON study that showed the superiority of FASLODEX over anastrozole (ARIMIDEX) in a first-line setting in postmenopausal women with locally advanced or hormone receptor-positive (HR+) breast cancer who had not received prior hormone-based therapy.
  • FASLODEX was previously approved to treat relapsed/refractory breast cancer patients who received prior anti-estrogen therapy.

Recommended For You

More Trending News

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC